文献速递肿瘤 PET/CT核素与放射性配体治疗

111In-DOTA-5D3:靶向前列腺特异性膜抗原的SPECT替代显像剂评价

Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.
PubMed 文献 · J Nucl Med · 2018-09-20

研究在PSMA阳性与阴性前列腺癌移植瘤小鼠中评价111In-DOTA-5D3的SPECT/CT显像、生物分布与剂量学,PSMA阳性肿瘤摄取在注射后24小时达峰并维持至72小时,肝脏吸收剂量最高(0.5 mGy/MBq),结论认为其可作为PSMA表达恶性组织显像及治疗的替代显像剂。

要点

  • PSMA阳性PC3 PIP肿瘤摄取于注射后24小时达峰,并维持高水平至72小时。
  • 共注射10倍和50倍过量未标记抗体显著降低PSMA阳性肿瘤及唾液腺摄取,但未降低肾脏与泪腺摄取。
  • 肝脏吸收剂量最高(0.5 mGy/MBq),唾液腺、泪腺及骨髓吸收剂量低。

核心结论

  • 111In-DOTA-5D3是一种新型放射性标记抗体,可用于PSMA表达恶性组织的显像,并作为治疗的替代显像剂。

研究设计与样本

  • 研究在雄性NOD/SCID小鼠右、左胁分别移植人PSMA阳性PC3 PIP与PSMA阴性PC3 flu前列腺癌,于注射后2、24、48、72和192小时行生物分布与SPECT显像。
  • 同时在无瘤健康雄性CD-1小鼠中行生物分布,并在24小时通过共注射10倍和50倍过量5D3行阻断实验以确定PSMA结合特异性。
  • 吸收剂量基于小鼠生物分布数据,按器官重量经OLINDA/EXM换算至人类成年男性。

主要发现

  • 111In-DOTA-5D3的比活度约为2.24 ± 0.74 MBq/μg(60.54 ± 20 μCi/μg)。
  • PSMA阳性PC3 PIP肿瘤摄取在注射后24小时达峰并维持至72小时;血液、脾、肝、心、肺等正常组织摄取在注射后2小时最高。
  • 共注射10倍和50倍过量未标记抗体在24小时显著降低PSMA阳性PC3 PIP肿瘤及唾液腺摄取,但未降低肾脏与泪腺摄取。
  • 注射后192小时111In-DOTA-5D3自所有器官显著清除。
  • 肝脏吸收剂量最高(0.5 mGy/MBq),其次为脾和肾脏;唾液腺、泪腺及骨髓吸收剂量低。

临床怎么用

  • 111In-DOTA-5D3可作为PSMA表达恶性组织显像及治疗的替代显像剂用于SPECT/CT评价。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry. Methods: Radiolabeling, stability, cell uptake, and internalization of 111In-DOTA-5D3 were performed by established techniques. Biodistribution and SPECT imaging were done on male nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice bearing human PSMA(+) PC3 PIP and PSMA(-) PC3 flu prostate cancer xenografts on the upper right and left flanks, respectively, at 2, 24, 48, 72, and 192 h after injection. Biodistribution was also evaluated in tumor-free, healthy male CD-1 mice. Blocking studies were performed by coinjection of a 10-fold and 50-fold excess of 5D3 followed by biodistribution at 24 h to determine PSMA binding specificity. The absorbed radiation doses were calculated on the basis of murine biodistribution data, which were translated to a human adult man using organ weights as implemented in OLINDA/EXM. Results:111In-DOTA-5D3 was synthesized with specific activity of approximately 2.24 ± 0.74 MBq/μg (60.54 ± 20 μCi/μg). Distribution of 111In-DOTA-5D3 in PSMA(+) PC3 PIP tumor peaked at 24 h after injection and remained high until 72 h. Uptake in normal tissues, including the blood, spleen, liver, heart, and lungs, was highest at 2 h after injection. Coinjection of 111In-DOTA-5D3 with a 10- and 50-fold excess of nonradiolabeled antibody significantly reduced PSMA(+) PC3 PIP tumor and salivary gland uptake at 24 h but did not reduce uptake in kidneys and lacrimal glands. Significant clearance of 111In-DOTA-5D3 from all organs occurred at 192 h. The highest radiation dose was received by the liver (0.5 mGy/MBq), followed by the spleen and kidneys. Absorbed radiation doses to the salivary and lacrimal glands and bone marrow were low. Conclusion:111In-DOTA-5D3 is a new radiolabeled antibody for imaging and a surrogate for therapy of malignant tissues expressing PSMA.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Banerjee SR, Kumar V, Lisok A, et al. Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. J Nucl Med. 2018. PMID: 30237212. doi:10.2967/jnumed.118.214403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。